Reported Earnings • Aug 06
First quarter 2027 earnings released: EPS: US$5.17 (vs US$6.28 in 1Q 2026) First quarter 2027 results: EPS: US$5.17 (down from US$6.28 in 1Q 2026). Revenue: US$105.4b (up 7.7% from 1Q 2026). Net income: US$614.0m (down 22% from 1Q 2026). Profit margin: 0.6% (down from 0.8% in 1Q 2026). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 6.4% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has increased by 24% per year, which means it is tracking significantly ahead of earnings growth. Declared Dividend • Jul 24
Fourth quarter dividend of US$0.94 announced Shareholders will receive a dividend of US$0.94. Ex-date: 1st September 2026 Payment date: 1st October 2026 Dividend yield will be 0.4%, which is lower than the industry average of 3.3%. Payout Ratios Payout ratio: 8%. Cash payout ratio: 7%. Duyuru • Jul 23
McKesson Corporation announces Quarterly dividend, payable on October 01, 2026 McKesson Corporation announced Quarterly dividend of USD 0.9400 per share payable on October 01, 2026, ex-date on September 01, 2026 and record date on September 01, 2026. Duyuru • Jul 01
McKesson Corporation Announces Management Changes, Effective August 1, 2026 McKesson Corporation announced that on June 29, 2026, Thomas L. Rodgers, the company's Executive Vice President, Chief Strategy and Business Development Officer and a named executive officer, gave notice of his intention to retire from that role. His last day of employment will be August 1, 2026. To support an orderly transition, the company appointed Ramesh Srinivasan as Executive Vice President, Chief Strategy Officer, effective on August 1, 2026. Duyuru • Jun 25
McKesson Corporation to Report Q1, 2027 Results on Aug 05, 2026 McKesson Corporation announced that they will report Q1, 2027 results on Aug 05, 2026 Duyuru • Jun 15
McKesson Corporation, Annual General Meeting, Jul 22, 2026 McKesson Corporation, Annual General Meeting, Jul 22, 2026. Declared Dividend • May 20
Fourth quarter dividend of US$0.82 announced Shareholders will receive a dividend of US$0.82. Ex-date: 1st June 2026 Payment date: 1st July 2026 Dividend yield will be 0.4%, which is lower than the industry average of 3.3%. Payout Ratios Payout ratio: 8%. Cash payout ratio: 7%. Duyuru • Apr 23
McKesson Corporation Declares Regular Dividend, Payable on July 1, 2026 The Board of Directors of McKesson Corporation declared a regular dividend of 82 cents per share of common stock. The dividend will be payable on July 1, 2026, to shareholders of record on June 1, 2026. Duyuru • Apr 22
Apollo Global Management, Inc. (NYSE:APO) entered into a definitive agreement to acquire 13% stake in McKesson Medical-Surgical Inc. from McKesson Corporation (NYSE:MCK) for $1.3 billion. Apollo Global Management, Inc. (NYSE:APO) entered into a definitive agreement to acquire 13% stake in McKesson Medical-Surgical Inc. from McKesson Corporation (NYSE:MCK) for $1.3 billion on April 20, 2026. The consideration consists of convertible preferred equity of Apollo Global Management, Inc. having a value of $1.25 billion to be issued for common equity of McKesson Medical-Surgical Inc. Following the acquisition, McKesson will retain operating control and majority ownership of MMS and consolidate the results for financial reporting.
The transaction is subject to regulatory approvals and customary closing conditions.
Tracey Zaccone, Michael Anastasio, Salvatore Vanchieri, and Julian Azran of Latham & Watkins LLP acted as legal advisor for Apollo Global Management, Inc. Alan F. Denenberg and Michael Diz, Jason Bassetti, Patrick E. Sigmon, Liang Zhang, Adam Kaminsky, Frank Azzopardi, and Suzanne Munck af Rosenschold of Davis Polk & Wardwell LLP acted as legal advisor for McKesson Corporation. Duyuru • Mar 06
McKesson Corporation to Report Q4, 2026 Results on May 07, 2026 McKesson Corporation announced that they will report Q4, 2026 results After-Market on May 07, 2026 Duyuru • Jan 28
Mckesson Corporation Declares Dividend, Payable on April 1, 2026 McKesson Corporation declares regular dividend of 82 cents per share of common stock. The dividend will be payable on Aril 1, 2026 to shareholders of record on March 2, 2026. Duyuru • Dec 22
McKesson Corporation to Report Q3, 2026 Results on Feb 04, 2026 McKesson Corporation announced that they will report Q3, 2026 results After-Market on Feb 04, 2026 Duyuru • Oct 30
McKesson Corporation Declares Quarterly Dividend on Common Stock, Payable on January 2, 2026 The Board of Directors of McKesson Corporation declared a regular dividend of 82 cents per share of common stock. The dividend will be payable on January 2, 2026 to shareholders of record on December 1, 2025. Duyuru • Sep 23
McKesson Corporation to Report Q2, 2026 Results on Nov 05, 2025 McKesson Corporation announced that they will report Q2, 2026 results at 4:00 PM, US Eastern Standard Time on Nov 05, 2025 Duyuru • Jul 30
Mckesson Corporation Declares Regular Dividend, Payable on October 1, 2025 The Board of Directors of McKesson Corporation declared a regular dividend of $0.82 per share of common stock, a 15% increase from $0.71 per share in the prior quarter. The dividend will be payable on October 1, 2025, to stockholders of record on September 2, 2025. Duyuru • Jun 26
McKesson Corporation to Report Q1, 2026 Results on Aug 06, 2025 McKesson Corporation announced that they will report Q1, 2026 results After-Market on Aug 06, 2025 Duyuru • Jun 23
McKesson Corporation, Annual General Meeting, Jul 30, 2025 McKesson Corporation, Annual General Meeting, Jul 30, 2025. Duyuru • May 01
McKesson Corporation Declares Quarterly Dividend, Payable on July 1, 2025 The Board of Directors of McKesson Corporation declared a regular dividend of 71 cents per share of common stock. The dividend will be payable on July 1, 2025, to stockholders of record on June 2, 2025. Duyuru • Apr 16
McKesson Unveils Precision Care Companion, Revolutionizing Precision Medicine in Community Oncology McKesson has launched a transformative initiative that will address the clinical challenges and administrative burden practices face in this new era of biomarker-directed oncology care. Precision Care Companion (PCC) is a consortium of industry experts, led by McKesson, that helps healthcare practices improve patient care. They do this through a multi-faceted approach that includes providing targeted education, technology enhancements, operational best practices, and detailed analytics on biomarker testing rates for different cancer diagnoses. The consortium model was intentionally chosen for its ability to unite diverse perspectives - physicians, clinicians, industry partners, and business leaders - creating a collaborative environment that drives innovation, uncovers real-world clinical challenges, and accelerates the adoption of precision technologies and therapies. With this innovative approach, McKesson is pioneering a new era in cancer treatment, enhancing the adoption of targeted therapies, and improving patient outcomes across community oncology. PCC is being deployed across The US Oncology Network (The Network), which supports more than 2,750 independent, community-based providers. This implementation allows the PCC team to support each step of the patient care journey -- from test ordering and results review to guideline-informed targeted therapy decisions -- and collate analytics and best practices to share across participating practices, driving continuous improvement in precision oncology. In addition to enabling enhanced clinical decision support within Ontada's iKnowMedSM electronic health record (EHR), a key focus of the program is to provide meaningful education and support to practices in a format that works best for them. All PCC participants have access to a robust range of educational and consultative services to meet their specific needs. Offerings include monthly master class webinars, a precision medicine boot camp, a molecular helpline for urgent questions about a specific patient's biomarker test results, and lab-agnostic molecular tumor boards. Duyuru • Apr 03
McKesson Corporation (NYSE:MCK) completed the acquisition of 80% stake in PRISM Vision Group from Quad-C Management, Inc. McKesson Corporation (NYSE:MCK) signed a definitive agreement to acquire 80% stake in PRISM Vision Group from Quad-C Management, Inc. for approximately $850 million on February 4, 2025. A cash consideration of $850 million will be paid by McKesson Corporation. PRISM Vision physicians will continue to retain a 20% interest in PRISM Vision. The transaction is subject to customary closing conditions, including necessary regulatory clearances.
David S. Ivill, Kristian A. Werling, Hunter R. Sharp, Joseph M. Parise, and Andrea Zazulia of McDermott Will & Emery LLP acted as legal advisor for PRISM Vision Group. Alan F. Denenberg, Jason Bassetti, Patrick E. Sigmon, Adam Kaminsky, Frank Azzopardi, and Suzanne Munck af Rosenschold of Davis Polk & Wardwell LLP acted as legal advisor for McKesson Corporation. Valentina Famparska, Roger J. Griesmeyer, Dilen Kumar, and M. Ramana Rameswaran of Katten Muchin Rosenman LLP acted as legal advisor for PRISM Vision Group.
McKesson Corporation (NYSE:MCK) completed the acquisition of 80% stake in PRISM Vision Group from Quad-C Management, Inc. on April 2, 2025. Duyuru • Apr 02
McKesson Corporation to Report Q4, 2025 Results on May 08, 2025 McKesson Corporation announced that they will report Q4, 2025 results After-Market on May 08, 2025 Duyuru • Feb 04
McKesson Corporation (NYSE:MCK) agreed to acquire 80% stake in PRISM Vision Group from Quad-C Management, Inc. for approximately $850 million. McKesson Corporation (NYSE:MCK) agreed to acquire 80% stake in PRISM Vision Group from Quad-C Management, Inc. for approximately $850 million on February 4, 2025. A cash consideration of $850 million will be paid by McKesson Corporation. PRISM Vision physicians will continue to retain a 20% interest in PRISM Vision. The transaction is subject to approval by regulatory board / committee. Duyuru • Jan 30
McKesson Corporation Declares Regular Dividend, Payable on April 1, 2025 The board of directors of McKesson Corporation declared a regular dividend of 71 cents per share of common stock. The dividend will be payable on April 1, 2025, to stockholders of record on March 3, 2025. Duyuru • Dec 30
McKesson Corporation to Report Q3, 2025 Results on Feb 05, 2025 McKesson Corporation announced that they will report Q3, 2025 results After-Market on Feb 05, 2025 Valuation Update With 7 Day Price Move • Nov 14
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to €580, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 13x in the Healthcare industry in Germany. Total returns to shareholders of 204% over the past three years. Duyuru • Nov 12
McKesson, Oracle, Thoma Bravo Reportedly Among Finalists to Acquire Veradigm McKesson Corporation (NYSE:MCK) and Oracle Corporation (NYSE:ORCL) are among the finalists seeking to acquire electronic medical records company Veradigm Inc. (OTCPK:MDRX), Axios reported on November 10, 2024, citing sources. According to the report, a deal is expected to top Veradigm’s $1 billion market cap due to the lower antitrust risk from the incoming Trump administration. One source was quoted as saying that the companies and private-equity firm Thoma Bravo could possibly have asked for a small discount due to possible increased antitrust scrutiny due to their medical data holdings. Axios reported that sources said Thoma Bravo was particularly interested due to its NextGen portfolio company. The sources reportedly said that CVS Health (CVS) had looked at Veradigm but dropped out amid its own strategic review. Axios reported that a deal is expected to be reached by Thanksgiving, the sources said. Veradigm, McKesson, Oracle, and Thoma Bravo did not immediately respond to requests for comment by Seeking Alpha. New Risk • Nov 07
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 21% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Negative equity (-US$2.6b). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (0.8% net profit margin). Reported Earnings • Nov 07
Second quarter 2025 earnings released: EPS: US$1.87 (vs US$4.95 in 2Q 2024) Second quarter 2025 results: EPS: US$1.87 (down from US$4.95 in 2Q 2024). Revenue: US$93.7b (up 21% from 2Q 2024). Net income: US$241.0m (down 64% from 2Q 2024). Profit margin: 0.3% (down from 0.9% in 2Q 2024). Revenue is forecast to grow 8.0% p.a. on average during the next 3 years, compared to a 3.6% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has only increased by 42% per year, which means it is significantly lagging earnings growth. Declared Dividend • Nov 03
First quarter dividend of US$0.71 announced Shareholders will receive a dividend of US$0.71. Ex-date: 2nd December 2024 Payment date: 2nd January 2025 Dividend yield will be 0.5%, which is lower than the industry average of 3.3%. Payout Ratios Payout ratio: 11%. Cash payout ratio: 11%. Duyuru • Oct 31
McKesson Corporation Declares Quarterly Dividend, Payable on January 2, 2025 The Board of Directors of McKesson Corporation declared a regular dividend of 71 cents per share of common stock. The dividend will be payable on January 2, 2025, to stockholders of record on December 2, 2024. Duyuru • Oct 01
McKesson Launches InspiroGene, a Dedicated Business to Guide and Support the Commercialization of Cell and Gene Therapies McKesson Corporation announced the launch of InspiroGene™ by McKesson, a dedicated business focused solely on supporting the commercialization of cell and gene therapies (CGTs). With a scalable, flexible suite of services and an experienced leadership team, InspiroGene enables manufacturers, payers, and providers to navigate the complex CGT commercialization landscape to ensure patients can access the life-changing treatments they need. InspiroGene brings unparalleled experience in every stage of the CGT life cycle and has established the following solutions to address the complex challenges of bringing CGTs to market: Third-party logistics (3PL) programs that meet the unique demands of CGT manufacturers, with financial management solutions, logistics, and cutting-edge data analytics to provide seamless operations for CGTs. Specialty distribution services that leverage McKesson’s extensive supply chain network, offering high-touch logistics and advanced data analytics to ensure CGTs reach patients efficiently and effectively. Biologics specialty pharmacy solutions dedicated to CGTs, including precision dispensing to expedite time to treatment, and patient management services to efficiently address the unique needs of patients based on therapy type. CGT dedicated patient hub that provides tailored access and support services for patients, as well as operational case management for providers, patients, and caregivers. In addition, InspiroGene offers a technology platform that provides visibility within the CGT value chain by integrating product data and financial flows to empower CGT manufacturers, providers, and patients to deliver exceptional care and achieve transformative clinical outcomes. Duyuru • Sep 24
McKesson Corporation to Report Q2, 2025 Results on Nov 06, 2024 McKesson Corporation announced that they will report Q2, 2025 results After-Market on Nov 06, 2024 Upcoming Dividend • Aug 23
Upcoming dividend of US$0.71 per share Eligible shareholders must have bought the stock before 30 August 2024. Payment date: 01 October 2024. Payout ratio is a comfortable 11% and this is well supported by cash flows. Trailing yield: 0.5%. Lower than top quartile of German dividend payers (4.8%). Lower than average of industry peers (3.3%). Reported Earnings • Aug 08
First quarter 2025 earnings released: EPS: US$7.05 (vs US$7.07 in 1Q 2024) First quarter 2025 results: EPS: US$7.05 (down from US$7.07 in 1Q 2024). Revenue: US$79.3b (up 6.4% from 1Q 2024). Net income: US$915.0m (down 4.5% from 1Q 2024). Profit margin: 1.2% (down from 1.3% in 1Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 8.4% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 78% per year but the company’s share price has only increased by 51% per year, which means it is significantly lagging earnings growth. Declared Dividend • Aug 05
Fourth quarter dividend of US$0.71 announced Shareholders will receive a dividend of US$0.71. Ex-date: 30th August 2024 Payment date: 1st October 2024 Dividend yield will be 0.4%, which is lower than the industry average of 3.3%. Payout Ratios Payout ratio: 11%. Cash payout ratio: 9%. Duyuru • Aug 02
McKesson Corporation Declares Regular Dividend on Common Stock, Payable on October 1, 2024 The Board of Directors of McKesson Corporation declared a regular dividend of $0.71 per share of common stock, a 15% increase from $0.62 per share in the prior quarter. The dividend will be payable on October 1, 2024, to stockholders of record on September 2, 2024. Duyuru • Jun 27
McKesson Corporation to Report Q1, 2025 Results on Aug 07, 2024 McKesson Corporation announced that they will report Q1, 2025 results After-Market on Aug 07, 2024 Duyuru • Jun 10
McKesson Corporation, Annual General Meeting, Jul 31, 2024 McKesson Corporation, Annual General Meeting, Jul 31, 2024. Duyuru • Jun 05
Mckesson Corporation Elects Deborah Dunsire as New Director McKesson Corporation announced that the McKesson board of directors has elected Dr. Deborah Dunsire as a director and member of the Compensation and Talent Committee and Finance Committee, effective June 3, 2024. Dr. Dunsire joins the board with over 30 years of experience leading large, matrixed organizations in the biopharmaceutical, oncology and other specialty industries. Most recently, she retired from her role as president and chief executive officer of H. Lundbeck A/S, a biopharmaceutical company specializing in developing and delivering transformative therapies for brain diseases. Prior to that, she held executive leadership roles for several pharmaceutical companies including XTuit Pharmaceuticals, FORUM Pharmaceuticals, Millennium: The Takeda Oncology Company and Millennium Pharmaceuticals. Dr. Dunsire started her career as a primary care physician in Johannesburg, South Africa. Dr. Dunsire currently serves on the boards of directors of Syros Pharmaceuticals Inc. and Ultragenyx Pharmaceutical Inc. She received her medical degree from the University of Witwatersrand in Johannesburg, South Africa. Board members Linda Mantia, who is no longer independent, and Susan Salka, who has served on the board for almost ten years, will not be standing for re-election at the 2024 Annual Meeting of Shareholders. Upon the election of all proposed director nominees at the Annual Meeting, the size of the board will be reduced to 11 members, 10 of whom are independent. Upcoming Dividend • May 27
Upcoming dividend of US$0.62 per share Eligible shareholders must have bought the stock before 03 June 2024. Payment date: 01 July 2024. Payout ratio is a comfortable 11% and this is well supported by cash flows. Trailing yield: 0.4%. Lower than top quartile of German dividend payers (4.6%). Lower than average of industry peers (3.0%). Reported Earnings • May 08
Full year 2024 earnings released: EPS: US$22.54 (vs US$25.25 in FY 2023) Full year 2024 results: EPS: US$22.54 (down from US$25.25 in FY 2023). Revenue: US$309.0b (up 12% from FY 2023). Net income: US$3.00b (down 16% from FY 2023). Profit margin: 1.0% (down from 1.3% in FY 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 8.1% p.a. on average during the next 3 years, compared to a 4.4% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 93% per year but the company’s share price has only increased by 45% per year, which means it is significantly lagging earnings growth. Declared Dividend • Apr 26
Third quarter dividend of US$0.62 announced Shareholders will receive a dividend of US$0.62. Ex-date: 3rd June 2024 Payment date: 1st July 2024 Dividend yield will be 0.5%, which is lower than the industry average of 3.3%. Payout Ratios Payout ratio: 10%. Cash payout ratio: 11%. Duyuru • Apr 25
McKesson Corporation Declares Quarterly Dividend, Payable on June 3, 2024 The Board of Directors of McKesson Corporation declared a regular dividend of 62 cents per share of common stock. The dividend will be payable on July 1, 2024, to stockholders of record on June 3, 2024. Duyuru • Mar 28
McKesson Corporation to Report Q4, 2024 Results on May 07, 2024 McKesson Corporation announced that they will report Q4, 2024 results After-Market on May 07, 2024 Upcoming Dividend • Feb 22
Upcoming dividend of US$0.62 per share Eligible shareholders must have bought the stock before 29 February 2024. Payment date: 01 April 2024. Payout ratio is a comfortable 10% and this is well supported by cash flows. Trailing yield: 0.5%. Lower than top quartile of German dividend payers (5.2%). Lower than average of industry peers (3.2%). Reported Earnings • Feb 08
Third quarter 2024 earnings released: EPS: US$4.45 (vs US$7.71 in 3Q 2023) Third quarter 2024 results: EPS: US$4.45 (down from US$7.71 in 3Q 2023). Revenue: US$80.9b (up 15% from 3Q 2023). Net income: US$589.0m (down 45% from 3Q 2023). Profit margin: 0.7% (down from 1.5% in 3Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 6.9% p.a. on average during the next 3 years, while revenues in the Healthcare industry in Germany are expected to remain flat. Over the last 3 years on average, earnings per share has increased by 102% per year but the company’s share price has only increased by 47% per year, which means it is significantly lagging earnings growth. Declared Dividend • Feb 04
Second quarter dividend of US$0.62 announced Shareholders will receive a dividend of US$0.62. Ex-date: 29th February 2024 Payment date: 1st April 2024 Dividend yield will be 0.5%, which is lower than the industry average of 3.3%. Payout Ratios Payout ratio: 9%. Cash payout ratio: 8%. Board Change • Feb 01
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Independent Director Kevin Ozan was the last director to join the board, commencing their role in 2024. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Duyuru • Feb 01
Mckesson Corporation Declares Quarterly Dividend, Payable on April 1, 2024 The Board of Directors of McKesson Corporation declared a regular dividend of 62 cents per share of common stock. The dividend will be payable on April 1, 2024, to stockholders of record on March 1, 2024. Duyuru • Jan 13
McKesson Corporation Reportedly Seeks Buyers for Canada's Rexall Pharmacy McKesson Corporation (NYSE:MCK) is planning to sell Canadian drugstore chain Rexall Pharma Plus Ltd. (Rexall Pharmacy Group), a source familiar with the process told Reuters on 12 January 2024, seven years after the U.S. drug distributor bought the business for about CAD 3 billion ($2.2 billion). McKesson has mandated CIBC (CM.TO) as a sellside financial advisor, according to the source. A spokesperson for CIBC declined to comment. McKesson bought the business in 2016 from Katz Group to strengthen its position in Canada's pharmaceutical supply chain. Rexall operates 400 pharmacies across Canada and employs 8,000 people, according to its website. It also has a pharmaceutical distribution arm. Rival Shoppers Drug Mart claims to be Canada's leading pharmacy retailer with more than 1,300 locations across the country, its website shows. Rexall did respond to multiple requests for comment, while McKesson declined to comment. McKesson has been in contact with prospective buyers for Rexall since the summer, according to the source, who said the company was on its second round of offers with no final date for bids. A sale may not include Rexall's pharmaceutical distribution arm, which is what some potential bidders are interested in, the source said. The Globe and Mail, which first reported the story, said McKesson could remain a Rexall partner by supplying the chain through the distribution business. Grocery stores, rival pharmacies and private equity companies are all potential candidates for the business, the source said. Duyuru • Jan 10
McKesson Corporation (NYSE:MCK) acquired Compile, Inc. McKesson Corporation (NYSE:MCK) acquired Compile, Inc. on January 4, 2024.McKesson Corporation (NYSE:MCK) completed the acquisition of Compile, Inc. on January 4, 2024. Duyuru • Jan 09
Mckesson Corporation Elects Kevin Ozan as New Director The McKesson board of directors has elected Kevin Ozan as director and member of the Audit Committee and Finance Committee, effective January 8, 2024. With the election of Ozan, McKesson’s board of directors increases from 11 to 12 members, 11 of whom are independent. Ozan recently retired from his role as senior executive vice president of strategic initiatives at McDonald’s Corporation. During his 25-year tenure with the global food service retailer, Ozan also served as executive vice president and chief financial officer and held multiple leadership roles overseeing financial and investor relations teams. Prior to McDonald’s, he worked for over a decade in Ernst & Young’s audit and mergers and acquisitions practices. In addition to McKesson, Ozan currently serves on the board of Cineworld, a private company with one of the largest global cinema businesses. Ozan holds a bachelor’s degree in accounting from the University of Michigan and a master’s degree in business from the Kellogg School of Management at Northwestern University. Duyuru • Dec 28
McKesson Corporation to Report Q3, 2024 Results on Feb 07, 2024 McKesson Corporation announced that they will report Q3, 2024 results After-Market on Feb 07, 2024 Duyuru • Dec 13
McKesson Appoints Crystal Lennartz to Health Mart and Health Mart Atlas McKesson appointed Crystal Lennartz, Pharm.D., MBA, to President of Health Mart, an independent pharmacy franchise, and Health Mart Atlas™, a pharmacy services administrative organization (PSAO). As President, Lennartz will focus on strengthening the overall health of Health Mart and Health Mart Atlas pharmacy members and elevating the role they play in people’s lives. Lennartz is a highly accomplished pharmacist, healthcare leader and advocate with more than 20 years of experience in managed care, clinical services, pharmacy operations, strategy and business development. Lennartz, whose career started as a pharmacist, has been with McKesson for more than a decade in various roles of increasing responsibility. Most recently, she served as Vice President & General Manager, Health Mart Atlas & Atlas Specialty. During her time in this role, Lennartz led Health Mart Atlas to be the largest, top-performing PSAO in the market, offering centralized managed care solutions for pharmacies. Last year, she also led the development and implementation of Atlas Specialty, bringing the strength of Health Mart Atlas to support specialty pharmacies. In addition, Lennartz spent six years on the Health Mart leadership team, including serving as Chief Pharmacist. Lennartz has both a Doctor of Pharmacy and Master of Business Administration from Drake University after which she completed an APhA-ASHP Accredited Residency in Pharmacy Practice with emphasis in Community Care. Upcoming Dividend • Nov 23
Upcoming dividend of US$0.62 per share at 0.5% yield Eligible shareholders must have bought the stock before 30 November 2023. Payment date: 02 January 2024. Payout ratio is a comfortable 8.8% and this is well supported by cash flows. Trailing yield: 0.5%. Lower than top quartile of German dividend payers (5.0%). Lower than average of industry peers (3.2%). Reported Earnings • Nov 02
Second quarter 2024 earnings released: EPS: US$4.93 (vs US$6.51 in 2Q 2023) Second quarter 2024 results: EPS: US$4.93 (down from US$6.51 in 2Q 2023). Revenue: US$77.2b (up 10% from 2Q 2023). Net income: US$664.0m (down 29% from 2Q 2023). Profit margin: 0.9% (down from 1.3% in 2Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 6.4% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 85% per year but the company’s share price has only increased by 44% per year, which means it is significantly lagging earnings growth. Duyuru • Nov 02
McKesson Corporation Announces Management Changes On October 27, 2023, Lori A. Schechter, the Chief Legal Officer of McKesson Corporation, gave notice of her intention to retire from that role as further described in Exhibit 99.1 under the heading Executive Leadership Transition. On November 1, 2023, the Company announced that Michele Lau is expected to become the Company’s Chief Legal Officer as further described in Exhibit 99.1 under the heading Executive Leadership Transition. Lori Schechter, Executive Vice President, Chief Legal Officer & General Counsel, has made the decision to retire from McKesson in June 2024. On January 1, 2024, Lori will assume the role of Board and Enterprise Risk Advisor and step down as an Executive Officer of the company, a role she has held since June 2014. With Lori’s decision to retire, the company announced the appointment of Michele Lau as Executive Vice President and Chief Legal Officer, effective January 1, 2024. For the past two and a half years, Michele has served as Chief Legal Officer & Corporate Secretary for GoDaddy. Prior to that role, Michele spent thirteen years as a member of McKesson’s General Counsel Organization, most recently as Senior Vice President, Corporate Secretary & Associate General Counsel. Duyuru • Oct 27
McKesson Corporation Declares Quarterly Dividend, Payable on January 2, 2024 The Board of Directors of McKesson Corporation declared a regular dividend of 62 cents per share of common stock. The dividend will be payable on January 2, 2024, to stockholders of record on December 1, 2023. Duyuru • Sep 28
McKesson Corporation to Report Q2, 2024 Results on Nov 01, 2023 McKesson Corporation announced that they will report Q2, 2024 results at 4:00 PM, US Eastern Standard Time on Nov 01, 2023 Upcoming Dividend • Aug 24
Upcoming dividend of US$0.62 per share at 0.6% yield Eligible shareholders must have bought the stock before 31 August 2023. Payment date: 02 October 2023. Payout ratio is a comfortable 8.0% and this is well supported by cash flows. Trailing yield: 0.6%. Lower than top quartile of German dividend payers (4.9%). Lower than average of industry peers (3.0%). Reported Earnings • Aug 03
First quarter 2024 earnings released: EPS: US$7.07 (vs US$5.31 in 1Q 2023) First quarter 2024 results: EPS: US$7.07 (up from US$5.31 in 1Q 2023). Revenue: US$74.5b (up 11% from 1Q 2023). Net income: US$958.0m (up 25% from 1Q 2023). Profit margin: 1.3% (up from 1.1% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 5.7% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 72% per year but the company’s share price has only increased by 42% per year, which means it is significantly lagging earnings growth. Duyuru • Jul 25
McKesson Corporation Raises Quarterly Dividend, Payable on October 2, 2023 The Board of Directors of McKesson Corporation declared on July 21, 2023 a regular dividend of $0.62 per share of common stock, a 15% increase from $0.54 per share in the prior quarter. The dividend will be payable on October 2, 2023, to stockholders of record on September 1, 2023. Duyuru • Jun 29
McKesson Corporation to Report Q1, 2024 Results on Aug 02, 2023 McKesson Corporation announced that they will report Q1, 2024 results at 4:00 PM, US Eastern Standard Time on Aug 02, 2023 Duyuru • Jun 23
McKesson Unveils New Private Brand of Over-the-Counter Pharmacy Products McKesson announced the launch of Foster & Thrive™, a curated private brand of over-the-counter (OTC) health and wellness products. Launching Foster & Thrive unifies the company’s private brand portfolio—consolidating Health Mart® and Sunmark® branded OTC products—to offer expanded availability through increased production volumes and efficiencies that will help meet evolving patient needs and growing demand. McKesson considered every aspect of the customers’ journey—in and out of the pharmacy—and thoughtfully crafted four product categories to help patients find the items they need: ? Acute Care? – to relieve temporary illnesses such as allergies, pain, cold and flu, digestion, and smoking cessation. Diagnostic Care? – to check and track symptoms and vital signs with diagnostic products like thermometers and blood pressure monitors. Everyday Care? – to help mend the everyday ailments with products for first aid, daily living support, feminine care, and cosmetics. Preventative Care? – to help ensure continued health and wellness through vitamins that support immunity, nutrition, and other personal needs. McKesson’s goal is to seamlessly transition Health Mart and Sunmark items to the new Foster & Thrive brand by category. The transition will begin in July 2023 and continue through October 2024. Duyuru • Jun 12
McKesson Corporation, Annual General Meeting, Jul 21, 2023 McKesson Corporation, Annual General Meeting, Jul 21, 2023, at 08:30 Central Standard Time. Agenda: To consider election of eleven directors for a one-year term; to consider Ratification of Appointment of Deloitte & Touche LLP as the Company's Independent Registered Public Accounting Firm for Fiscal For Year 2024; to consider advisory vote on executive compensation; to consider Advisory vote on the frequency of the advisory vote on executive compensation; and to consider other matters. Upcoming Dividend • May 24
Upcoming dividend of US$0.54 per share at 0.5% yield Eligible shareholders must have bought the stock before 31 May 2023. Payment date: 03 July 2023. Payout ratio is a comfortable 8.3% and this is well supported by cash flows. Trailing yield: 0.5%. Lower than top quartile of German dividend payers (4.6%). Lower than average of industry peers (3.1%). Reported Earnings • May 09
Full year 2023 earnings released: EPS: US$25.25 (vs US$7.35 in FY 2022) Full year 2023 results: EPS: US$25.25 (up from US$7.35 in FY 2022). Revenue: US$276.7b (up 4.8% from FY 2022). Net income: US$3.56b (up 218% from FY 2022). Profit margin: 1.3% (up from 0.4% in FY 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 5.6% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has only increased by 41% per year, which means it is significantly lagging earnings growth. Upcoming Dividend • Feb 21
Upcoming dividend of US$0.54 per share at 0.6% yield Eligible shareholders must have bought the stock before 28 February 2023. Payment date: 03 April 2023. Payout ratio is a comfortable 9.2% and this is well supported by cash flows. Trailing yield: 0.6%. Lower than top quartile of German dividend payers (4.6%). Lower than average of industry peers (3.5%). Reported Earnings • Feb 03
Third quarter 2023 earnings released: EPS: US$7.71 (vs US$0.046 loss in 3Q 2022) Third quarter 2023 results: EPS: US$7.71 (up from US$0.046 loss in 3Q 2022). Revenue: US$70.5b (up 2.7% from 3Q 2022). Net income: US$1.08b (up US$1.09b from 3Q 2022). Profit margin: 1.5% (up from 0% in 3Q 2022). Revenue is forecast to grow 4.9% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has only increased by 31% per year, which means it is significantly lagging earnings growth. Duyuru • Jan 27
McKesson Corporation Declares Regular Dividend on Common Stock, Payable on April 3, 2023 The Board of Directors of McKesson Corporation declared a regular dividend of 54 cents per share of common stock. The dividend will be payable on April 3, 2023, to stockholders of record on March 1, 2023. Duyuru • Dec 29
McKesson Corporation to Report Q3, 2023 Results on Feb 01, 2023 McKesson Corporation announced that they will report Q3, 2023 results After-Market on Feb 01, 2023 Upcoming Dividend • Nov 23
Upcoming dividend of US$0.54 per share Eligible shareholders must have bought the stock before 30 November 2022. Payment date: 03 January 2023. Payout ratio is a comfortable 14% and this is well supported by cash flows. Trailing yield: 0.6%. Lower than top quartile of German dividend payers (4.9%). Lower than average of industry peers (4.0%). Board Change • Nov 16
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Independent Director W. Dunbar was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Valuation Update With 7 Day Price Move • Nov 12
Investor sentiment deteriorated over the past week After last week's 16% share price decline to €335, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 13x in the Healthcare industry in Germany. Total returns to shareholders of 163% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €622 per share. Reported Earnings • Nov 03
Second quarter 2023 earnings released: EPS: US$6.51 (vs US$1.73 in 2Q 2022) Second quarter 2023 results: EPS: US$6.51 (up from US$1.73 in 2Q 2022). Revenue: US$70.2b (up 5.4% from 2Q 2022). Net income: US$932.0m (up 249% from 2Q 2022). Profit margin: 1.3% (up from 0.4% in 2Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 5.0% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has increased by 45% per year, which means it is tracking significantly ahead of earnings growth. Upcoming Dividend • Aug 24
Upcoming dividend of US$0.54 per share Eligible shareholders must have bought the stock before 31 August 2022. Payment date: 03 October 2022. Payout ratio is a comfortable 20% and this is well supported by cash flows. Trailing yield: 0.6%. Lower than top quartile of German dividend payers (4.6%). Lower than average of industry peers (3.5%). Reported Earnings • Aug 04
First quarter 2023 earnings released: EPS: US$5.25 (vs US$3.13 in 1Q 2022) First quarter 2023 results: EPS: US$5.25 (up from US$3.13 in 1Q 2022). Revenue: US$67.2b (up 7.1% from 1Q 2022). Net income: US$766.0m (up 57% from 1Q 2022). Profit margin: 1.1% (up from 0.8% in 1Q 2022). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 1.3%, compared to a 2.7% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has increased by 38% per year, which means it is well ahead of earnings. Recent Insider Transactions • Jun 09
Executive VP & CFO recently sold €526k worth of stock On the 3rd of June, Britt Vitalone sold around 2k shares on-market at roughly €299 per share. In the last 3 months, they made an even bigger sale worth €8.5m. Britt has been a seller over the last 12 months, reducing personal holdings by €10m. Recent Insider Transactions • May 27
Executive VP & CFO recently sold €1.3m worth of stock On the 24th of May, Britt Vitalone sold around 4k shares on-market at roughly €303 per share. This was the largest sale by an insider in the last 3 months. This was Britt's only on-market trade for the last 12 months. Upcoming Dividend • May 24
Upcoming dividend of US$0.47 per share Eligible shareholders must have bought the stock before 31 May 2022. Payment date: 01 July 2022. Payout ratio is a comfortable 25% and this is well supported by cash flows. Trailing yield: 0.6%. Lower than top quartile of German dividend payers (4.2%). Lower than average of industry peers (2.7%). Reported Earnings • May 08
Full year 2022 earnings released: EPS: US$7.35 (vs US$28.26 loss in FY 2021) Full year 2022 results: EPS: US$7.35 (up from US$28.26 loss in FY 2021). Revenue: US$264.0b (up 11% from FY 2021). Net income: US$1.12b (up US$5.66b from FY 2021). Profit margin: 0.4% (up from net loss in FY 2021). Over the next year, revenue is expected to shrink by 1.1% compared to a 4.6% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has increased by 35% per year, which means it is well ahead of earnings. Board Change • Apr 27
High number of new directors There are 6 new directors who have joined the board in the last 3 years. Director W. Dunbar was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Upcoming Dividend • Feb 21
Upcoming dividend of US$0.47 per share Eligible shareholders must have bought the stock before 28 February 2022. Payment date: 01 April 2022. Payout ratio is a comfortable 20% and this is well supported by cash flows. Trailing yield: 0.7%. Lower than top quartile of German dividend payers (3.3%). Lower than average of industry peers (2.5%). Reported Earnings • Feb 04
Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat Third quarter 2022 results: US$0.046 loss per share (up from US$39.03 loss in 3Q 2021). Revenue: US$68.6b (up 9.6% from 3Q 2021). Net loss: US$7.00m (loss narrowed 100% from 3Q 2021). Profit margin: 0% (up from net loss in 3Q 2021). Revenue exceeded analyst estimates by 3.0%. Over the next year, revenue is forecast to stay flat compared to a 4.2% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 58% per year but the company’s share price has increased by 25% per year, which means it is well ahead of earnings. Board Change • Feb 02
High number of new directors There are 6 new directors who have joined the board in the last 3 years. Director Jim Hinton was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Recent Insider Transactions • Nov 24
Insider recently sold €1.7m worth of stock On the 22nd of November, Tracy Faber sold around 8k shares on-market at roughly €198 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €1.7m more than they bought in the last 12 months. Upcoming Dividend • Nov 23
Upcoming dividend of US$0.47 per share Eligible shareholders must have bought the stock before 30 November 2021. Payment date: 03 January 2022. Trailing yield: 0.8%. Lower than top quartile of German dividend payers (3.1%). Lower than average of industry peers (2.6%). Reported Earnings • Nov 02
Second quarter 2022 earnings released: EPS US$1.73 (vs US$3.56 in 2Q 2021) The company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2022 results: Revenue: US$66.6b (up 9.5% from 2Q 2021). Net income: US$267.0m (down 54% from 2Q 2021). Profit margin: 0.4% (down from 0.9% in 2Q 2021). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 109 percentage points per year, which is a significant difference in performance. Executive Departure • Oct 12
Independent Director Kenneth Washington has left the company On the 5th of October, Kenneth Washington's tenure as Independent Director ended after 2.3 years in the role. We don't have any record of a personal shareholding under Kenneth's name. A total of 4 executives have left over the last 12 months. The current median tenure of the management team is 2.25 years. Upcoming Dividend • Aug 24
Upcoming dividend of US$0.47 per share Eligible shareholders must have bought the stock before 31 August 2021. Payment date: 01 October 2021. Trailing yield: 0.9%. Lower than top quartile of German dividend payers (3.1%). Lower than average of industry peers (2.1%). Reported Earnings • Aug 05
First quarter 2022 earnings released: EPS US$3.13 (vs US$2.75 in 1Q 2021) The company reported a solid first quarter result with improved earnings and revenues, although profit margins were flat. First quarter 2022 results: Revenue: US$62.7b (up 13% from 1Q 2021). Net income: US$489.0m (up 9.9% from 1Q 2021). Profit margin: 0.8% (in line with 1Q 2021). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 99 percentage points per year, which is a significant difference in performance. Executive Departure • Aug 03
Independent Director Marie Knowles has left the company On the 23rd of July, Marie Knowles' tenure as Independent Director ended after 19.4 years in the role. We don't have any record of a personal shareholding under Marie's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 2.33 years. Executive Departure • Aug 03
Independent Director M. Jacobs has left the company On the 23rd of July, M. Jacobs' tenure as Independent Director ended after 22.6 years in the role. We don't have any record of a personal shareholding under Jacobs' name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 2.33 years. Executive Departure • Aug 03
Independent Director N. Coles has left the company On the 23rd of July, N. Coles' tenure as Independent Director ended after 7.2 years in the role. We don't have any record of a personal shareholding under Coles' name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 2.33 years. Upcoming Dividend • May 21
Upcoming dividend of US$0.42 per share Eligible shareholders must have bought the stock before 28 May 2021. Payment date: 01 July 2021. Trailing yield: 0.8%. Lower than top quartile of German dividend payers (3.2%). Lower than average of industry peers (2.1%). 
